A Case of COVID-19 in a patient with Pemphigus successfully managed with favipiravir

Abstract

COVID-19 is not only a respiratory disease, but a multisystem disease that can cause organ dysfunction and coagulation disorder associated with high mortality and morbidity, particularly in vulnerable populations. Severe complications can be seen especially in elderly patients with systemic disease and immunosuppressive patients. We present the case of COVID-19 that developed in a 38-year-old female patient with pemphigus successfully managed with favipiravir.

Keywords

• COVID-19
• Pemphigus
• Favipiravir

Favipiravir ile Başarılı Şekilde Tedavi Edilen Pemfiguslu bir COVID-19 Vakası

Abstract

COVID-19 sadece bir solunum hastalığı değil, aynı zamanda özellikle hassas popülasyonda yüksek mortalite ve morbidite ile ilişkili organ disfonksiyonuna ve pıhtılaşma bozukluğuna neden olabilen multisistemik bir hastalıktır. Özellikle sistemik hastalığı olan yaşlı hastalarda ve immünsüpresif hastalarda ciddi komplikasyonlar görülebilmektedir. Favipiravir ile başarılı bir şekilde tedavi edilen pemfiguslu 38 yaşındaki bir kadın hastada gelişen COVID-19 vakasını sunuyoruz.

Keywords

• COVİD-19
• Pemfigus
• Favipiravir

References

1. Demirbaş A, Elmas ÖF, Türsen Ü, Atasoy M, Lotti T. Superficial thrombophlebitis in a patient with COVID 19: Heparin treatment after evaluation of D-Dimer. Dermatol Ther. 2020;33(4): e13768.
2. Beyazçiçek Ö, Beyazçiçek E, Demir S. Are Blood Groups Protective Against COVID-19?. Konuralp Med J. 2021;13(1): 160-7.
3. Elmas ÖF, Demirbaş A, Türsen Ü, Atasoy M, Lotti T. Pemphigus and COVID-19: Critical overview of management with a focus on treatment choice. Dermatol Ther. 2020: e14265.
4. Shakshouk H, Daneshpazhooh M, Murrell DF, Lehman JS. Treatment considerations for patients with pemphigus during the COVID-19 pandemic. J Am Acad Dermatol. 2020;82(6): e235-e236.
5. Schmidt E. Rituximab as first-line treatment of pemphigus. Lancet. 2017;389(10083): 1956-8.
6. Karabay O, İnci M, Öğütlü A, Ekerbiçer H, Güçlü E, Dheir H, et al. Is it possible to predict mortality using initial data of adult patients hospitalized with COVID-19? A mortality prediction model in the early phase of COVID-19. Konuralp Med J. 2021;13(1): 36-44.
7. Kasperkiewicz M, Schmidt E, Fairley JA, Joly P, Payne AS, Yale ML, et al. Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic. J Eur Acad Dermatol Venereol. 2020;34(7): e302-e303.
8. Guidance from the EADV Task Force Autoimmune Blistering Diseases during the COVID-19 pandemic. The EADV Task force Autoimmune Blistering Diseases supports patients and their families during this difficult period of COVID-19 pandemic and provides the following advices. 2020.

9. Coomes EA, Haghbayan H. Favipiravir, an antiviral for COVID-19?. J Antimicrob Chemother. 2020;75(7): 2013-4.
10. Dheir H, Yaylacı S, Sipahi S, Şenocak D, Toptan H, Aşıcı N, et al. The effectiveness of favipiravir treatment in severe COVID-19 pneumonia: A single center experience. Konuralp Med J. 2021; 13(1): 4-10.
11. Nasir M, Perveen RA, Saha SK, Talha KA, Selina F, Islam MA. Systematic Review on Repurposing Use of Favipiravir Against SARS-CoV-2. Mymensingh Med J. 2020;29(3): 747-54.